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abstract
background: Requests for troponin T, a biomarker for myocardial infarction, may be sent in a variety of clinical situations. In 
most cases, a single sample 12 hours or more after symptom onset should be sufficient for diagnosis. We chose to investigate 
how troponin T testing is used in our hospital with emphasis on those who had serial rather than single troponin measurements 
during their hospital stay.
Methods: Prospective survey of 50 patients with serial troponin T requests out of a total of 321 patients who had troponin T 
levels measured during the same time period.
results: The time of symptom onset could be clearly identified in 40/50 patients. In 22 of these the first troponin was taken prior 
to 12 hours after symptom onset. For the 18 patients whose first troponin was taken after 12 hours, the second result remained 
in the same category (normal or high) as the first in all cases.  This was not the case for 3/10 patients whose first troponin was 
sent within 12 hours and was normal.  Early troponin results rarely affected immediate patient management and did not inform 
decisions about fibrinolytic therapy.
conclusions: Serial troponin testing was most commonly due to a sample being sent within 12 hours of symptom onset or to 
unnecessary repetition of an appropriately timed sample.  Patient management was rarely enhanced by early troponin testing.
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INtrODUctION
Recent years have seen increasing use of troponin testing in 
the setting of acute chest pain.  The sensitivity and specificity 
of troponin release as a marker of myocardial necrosis are 
such that the definition of acute myocardial infarction (AMI) 
has been rewritten to include troponin levels1. There has also 
been debate about diagnostic cut-off values and the clinical 
relevance of “borderline” troponin elevations2,3, which may 
be found in the absence of classical symptoms of cardiac 
ischaemia or electrocardiographic (ECG) changes in patients 
who are unwell for some other reason.  Guidelines emphasise 
that a troponin result should be interpreted in the clinical 
context and should be timed1. Troponin may not start to rise 
for several hours after symptom onset and although a raised 
troponin when the patient is first seen can be used to “rule in” 
AMI, there is some disparity in the recommended protocols 
for optimal timing of further samples if the initial one is 
negative4. However, both European and American guidelines 
agree that a normal troponin 12 hours after symptom onset 
excludes AMI5,6.
On the basis of anecdotal observations of repeated troponin 
samples in the same patients, and reports of delay in some 
results  becoming  available,  we  chose  to  investigate  how 
troponin  is  used  in  clinical  practice  in  our  hospital.  A 
preliminary  analysis  showed  that  during  a  single  month 
(October  2004)  501  patients  had  a  single  troponin  T 
request and 167 had two or more. We decided to investigate 
prospectively  the  group  of  patients  who  had  multiple 
requests during the same admission to answer the following 
questions:
1.  In patients who have serial troponin requests, how are they 
timed in relation to patient presentation?
2.  If an early measurement taken at presentation is normal is 
a second 12-hour test arranged?
3.  How  long  is  the  average  period  of  time  between 
venepuncture and a clinician seeing the result?
4.  Do early troponin results influence immediate clinical 
management?© The Ulster Medical Society, 2007.
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MEtHODs
During  the  first  18  days  of  May  2005,  on  each  weekday 
morning all troponin T requests from the previous 48 hours 
were reviewed and any patient having two or more tests were 
identified.  Each of these patients was visited by one of the 
clinicians participating in the study (BL, JM or RS) and their 
medical  notes  were  reviewed  with  a  data  collection  sheet 
designed  to  answer  the  questions  above.   The  time  taken 
to  transport  the  samples  to  the  laboratory,  time  between 
laboratory  receipt  of  the  sample  and  report  of  the  result, 
and time to look-up were obtained from the data trail on the 
laboratory computer system. Troponin T is measured using the 
Elecsys assay (Roche Diagnostics) and is available as a stat test 
24 hours a day.  The upper reference limit is 0.03 µg/L.
rEsUlts
During the survey period, 68 patients were identified who had 
at least two troponin T samples sent during a single hospital 
admission.  Complete clinical data were available for 50 and 
these form the study population.  The total number of patients 
for whom troponin T requests were processed during the 
survey was 321. 
The  majority  (33/50)  of  those  who  had  serial  troponin 
requests were new patients presenting via the Emergency 
Department (ED).  First assessment of these patients was 
split evenly between the hospital’s team of specialist chest 
pain nurses who are called to the ED to see any patient with 
acute chest pain, and ED senior house officers who tended 
Fig 1.  Flowchart illustrating usage of troponin T during survey period© The Ulster Medical Society, 2007.
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to see patients with alternative presenting symptoms such as 
dyspnoea.  Presenting symptoms are detailed in Table I. The 
remainder were inpatients on a variety of wards throughout 
the hospital and were assessed first by junior doctors on those 
wards.  Out of the 50 patients with serial requests, we noted 
one with a working diagnosis of ruptured abdominal aortic 
aneurysm and another of status epilepticus.  Forty-eight had 
ECG’s recorded on initial presentation.
In 10 of 50 patients with serial samples the time of symptom 
onset could not be clearly identified.  Of the remaining 40, 22 
had their first sample taken within 12 hours of symptom onset 
and 18 had it performed after 12 hours (figure 1). Of these 
18, eight were patients with chest pain who did not present 
until after 12 hours.
Of the 22 patients whose first troponin was taken early (within 
12 hours of symptom onset), 12 had elevated results. Eight 
of these were assessed by or discussed with the cardiology 
team and three were admitted to monitored cardiac beds. Two 
patients received fibrinolytic therapy, in both cases before the 
troponin T result had been seen.
In the 18 patients whose first sample was sent 12 hours or 
more after symptom onset, 10 had values below the reference 
limit and eight were high. In all 18 cases the second troponin 
result was in the same category (normal or high) as the first.
Seventeen  of  the  hundred  samples  included  in  this  audit 
were  not  labelled  with  the  time  of  venepuncture.  Those 
samples that were timed took a median time of 57 minutes 
to be transported to the laboratory (interquartile range 36-73 
minutes). The median time taken for the laboratory to process 
a sample and release the result was 50 minutes (interquartile 
range 41-67 minutes), and the subsequent median time taken 
for non-laboratory staff to view the result on the computer 
system was 81 minutes (interquartile range 16-184 minutes).   
This excludes one telephoned result and ten results which 
were not looked up within 12 hours of becoming available. 
If these results and the untimed samples are excluded, the 
median total time between venepuncture and non-laboratory 
staff viewing the result was 221 minutes (interquartile range 
118-306 minutes).  
DIscUssION
This survey provides an overview of how one of the most 
high profile and high-growth tests of recent years is used in 
clinical practice.  Most patients for whom the test is requested 
are managed with a single sample.  However a substantial 
minority (68/321; 21%) had two or more samples sent during 
a single hospital admission and these patients were the focus 
of the current survey to determine the clinical value of serial 
troponin sampling. 
Early troponin requesting (within 12 hours) was a common 
reason for duplicate samples being performed. Of 22 patients 
with early samples sent, we observed three in whom clinical 
management was potentially affected by the result of the 
early sample.  Early troponins may be used as part of an 
investigation protocol for chest pain such as the Sheffield 
protocol7, which recommends a single troponin measurement 
at 6 hours. This protocol however also involves continual 
ECG monitoring and exercise stress testing and as such is 
applicable to specialist chest pain units rather than general 
medical take-in through the ED. An early level is of value if it 
rules in AMI in a patient whose clinical findings and ECG are 
equivocal, thereby facilitating earlier management.  However 
we found that no patient received earlier thrombolytic therapy 
because of an early troponin T result and that only a minority 
(3/12) of patients who had a positive early troponin were 
immediately transferred to monitored cardiac beds.  Such 
observations raise questions about the clinical value of early 
troponin testing, including in patients in whom it is found to 
be elevated.
In cases of serial troponin samples another question of interest 
is whether both are necessary.  Guidelines state that in certain 
equivocal cases it is useful to demonstrate a rise and fall in 
troponin in order to diagnose an acute episode of cardiac 
ischaemia1.  However this indication for serial testing refers 
to atypical cases rather than the majority and is unlikely to 
explain many of the serial troponin samples that we observed. 
There is always a degree of redundancy in requesting with 
any diagnostic test but it is a particularly relevant issue where 
troponin is concerned given that chest pain is a common 
and important presenting symptom in the ED.  Furthermore 
troponin workload is difficult for laboratories to manage, as 
it is perceived that troponin measurements cannot be delayed 
or repeat troponin requests declined by the laboratory without 
the risk of harmful consequences to patients. However we did 
find that the problem of repeated troponin samples was less 
than it had appeared prior to the survey. We also found that 
although laboratory turnaround time for troponin is higher 
than ideal, it comprised under a quarter of the median total 
length of time between venepuncture and a clinician viewing 
the result. 
Among  18  patients  with  serial  troponin  samples  whose 
initial sample had been sent at least 12 hours from symptom 
onset, the subsequent result remained in the same category in 
every case.  This is a reassuring finding and underscores the 
reliability of the 12 hour troponin sample and the predictive 
value of this troponin T assay in clinical practice.  In contrast 
among 10 patients whose early troponin level was normal, the 
12 hour result was elevated in 3, highlighting the potential for 
diagnostic error when troponin levels are measured within 12 
hours of symptom onset.
Ta b l e  1
Main presenting symptoms (patients may have had more 
than one symptom)
Symptom Number of patients (n/50)
Chest pain
Dyspnoea
Dizziness / collapse
Abdominal / back pain
Vomiting
None of these
30
10
8
6
2
5© The Ulster Medical Society, 2007.
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The optimal role for troponin T sampling in the assessment of 
suspected acute ischaemic chest pain is as a single sample 12 
hours (or later) from the onset of symptoms.  We found that 
early samples rarely affected immediate patient management 
and  did  not  inform  decisions  about  fibrinolytic  therapy.   
Samples taken 12 hours or more after symptom onset do 
not need to be repeated in the absence of further ischaemic 
symptoms.
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